These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 20493428)
1. A new approach for evaluating bone turnover in chronic kidney disease. Tolouian R; Hernandez GT; Chiang WY; Gupta A Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428 [TBL] [Abstract][Full Text] [Related]
2. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Sprague SM; Bellorin-Font E; Jorgetti V; Carvalho AB; Malluche HH; Ferreira A; D'Haese PC; Drüeke TB; Du H; Manley T; Rojas E; Moe SM Am J Kidney Dis; 2016 Apr; 67(4):559-66. PubMed ID: 26321176 [TBL] [Abstract][Full Text] [Related]
4. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403 [TBL] [Abstract][Full Text] [Related]
5. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378 [TBL] [Abstract][Full Text] [Related]
6. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers . Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350 [TBL] [Abstract][Full Text] [Related]
7. Relationships between myocardial injury, all-cause mortality, vitamin D, PTH, and biochemical bone turnover markers in older patients with hip fractures. Fisher AA; Southcott EK; Srikusalanukul W; Davis MW; Hickman PE; Potter JM; Smith PN Ann Clin Lab Sci; 2007; 37(3):222-32. PubMed ID: 17709685 [TBL] [Abstract][Full Text] [Related]
8. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Haarhaus M; Monier-Faugere MC; Magnusson P; Malluche HH Am J Kidney Dis; 2015 Jul; 66(1):99-105. PubMed ID: 25843703 [TBL] [Abstract][Full Text] [Related]
9. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of bone resorption markers in hemodialysis patients. Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165 [TBL] [Abstract][Full Text] [Related]
11. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism. Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811 [TBL] [Abstract][Full Text] [Related]
12. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women. Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597 [TBL] [Abstract][Full Text] [Related]
13. [Serum beta-type I collagen carboxyterminal telopeptide (beta-CTXs) and bone involvement in chronic renal failure]. Oliveri B; Wittich AC; Nadal MA; Zeni SN Medicina (B Aires); 2005; 65(4):321-8. PubMed ID: 16193710 [TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and biochemical markers of bone metabolism in predialysis patients with chronic kidney disease. Fidan N; Inci A; Coban M; Ulman C; Kursat S J Investig Med; 2016 Apr; 64(4):861-6. PubMed ID: 26969749 [TBL] [Abstract][Full Text] [Related]
15. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis. Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546 [TBL] [Abstract][Full Text] [Related]
16. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study. Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874 [TBL] [Abstract][Full Text] [Related]
17. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638 [TBL] [Abstract][Full Text] [Related]
18. Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. Montalbán C; García-Unzueta MT; De Francisco AL; Amado JA Horm Metab Res; 1999 Jan; 31(1):14-7. PubMed ID: 10077343 [TBL] [Abstract][Full Text] [Related]
20. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]